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ABSTRACT 
Background and Objectives: It is thought that patients with diabetes mellitus (DM) have a poor prognosis after 
an acute myocardial infarction (AMI), but the effect of diabetes on the outcomes of hypertensive patients with AMIs has 
not been elucidated in the Korean population. The aim of this study was to investigate the effects of diabetes on long-
term clinical outcomes following AMIs in patients with hypertension. Subjects and Methods: Using data from the 
Korea Acute Myocardial Infarction Registry (November 2005 to December 2006), 2,233 hypertensive patients with 
AMIs were grouped as follows based on the presence of DM: group I, diabetic hypertension (n=892, 544 men, mean 
age=66.2±10.9 years); and group II, non-diabetic hypertension (n=1341, 938 men, mean age=63.9±12.8 years). 
The primary study outcomes included in-hospital death and major adverse cardiac events (MACE; cardiac death, 
myocardial infarction (MI), repeat percutaneous coronary intervention, and coronary artery bypass surgery) at the 1 
year follow-up. Results: Hypertensive patients with DM were older and more likely to be women. The diabetic 
group had lower blood pressure (p<0.001), a lower left ventricular ejection fraction (p<0.001), a more severe degree 
of heart failure (p<0.001), a longer duration of coronary care unit admission (p<0.001), and a higher incidence of 
hyperlipidemia (p=0.007). The N-terminal pro-brain natriuretic peptide level (4602.5±8710.6 pg/mL vs. 2320.8
±5837.9 pg/mL, p<0.001) was higher and the creatinine clearance (62.4±29.9 mL/min vs. 73.0±40.8 mL/min, 
p<0.001) was lower in the diabetic group than the non-diabetic group. Coronary angiographic findings revealed 
more frequent involvement of the left main stem (p=0.002) and multiple vessels (p<0.001) in the diabetic group. 
The rate of in-hospital death was higher in the diabetic group (p<0.001). During follow-up, the rates of composite 
MACE at 1 month, 6 months, and 12 months were higher in the diabetic group (p<0.001). Conclusion: In hy-
pertensive patients with AMI, DM was associated with worse clinical and angiographic features, with a higher risk 
of development of severe heart failure, and an increased risk of MACE on long-term clinical follow-up. (Korean 
Circ J 2009; 39:243-250) 
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Introduction 
 
Diabetes mellitus (DM) is a common disease with sub-
stantial morbidity and mortality.
1)2) Hypertension is a well-
known risk factor for coronary artery disease and there 
is considerable evidence for an increased prevalence of 
hypertension in diabetics, affecting up to 60%.
2-5) More-
over, each pathophysiologic disease entity serves to exa-
cerbate the other.
3)6) The presence of hypertension in dia-
betic patients significantly increases the risk of cardiovas-
cular disease (CVD), including acute coronary syndro-
me.
5)7) Generally, hypertension in type 2 diabetics clusters 
with other CVD risk factors, such as microalbuminuria, 
central obesity, insulin resistance, dyslipidemia, hyper-
coagulation, increased inflammation, and left ventricular 
hypertrophy.
5) This clustering of risk factors in diabetics 
ultimately results in the development of CVD, which is 
the major cause of premature mortality in patients with 
type 2 DM. Previous studies are in agreement that DM is 
an independent risk for mortality after an acute myocar-
dial infarction (AMI).
8-10) Also, other several studies have 
shown that hypertension is associated with a worse pro-
gnosis after an AMI.
11-13) Despite this consensus, the ef-
fect of DM on the outcomes of hypertensive patients 
following an AMI has not been clearly demonstrated 
within the Oriental population. 
Therefore, we conducted the present study to analyze 
the clinical impact of DM on patients with hypertension 
following an AMI who were registered in the Korea Acute 
Myocardial Infarction Registry (KAMIR). 
 
Subjects and Methods 
 
Patient population and study design 
The KAMIR is a prospective, multi-center, observati-
onal registry designed to examine current epidemiology, 
in-hospital management, and outcome of patients with 
AMIs in Korea for the commemoration of the 50th an-
niversary of the Korean Circulation Society.
14)15) Among 
the patients with AMIs, 2,233 hypertensive patients who 
were followed-up at 1 year were included in the present 
study. These patients were grouped as follows based on 
the presence of DM: group I, patients who were assigned 
to the diabetic hypertensive group (total 892, 544 males, 
mean age=66.2±10.9 years); and group II, patients who 
were assigned to the non-diabetic hypertensive group 
(total 1,341, 938 males, mean age=63.9±12.8 years). 
Hypertension was defined as a blood pressure ≥140/90 
mmHg, or when the patient was taking antihypertensive 
medication based on a history of diagnosed hypertension. 
DM was defined as a fasting plasma glucose level ≥126 
mg/dL, a random plasma glucose level ≥200 mg/dL, or 
when the patient was taking oral hypoglycemic agents or 
using subcutaneous insulin based on a history of diag-
nosed DM. Eligible patients for this study were required 
to have all three of the following: 1) symptoms of ische-
mia increasing or occurring at rest, 2) an elevated cardiac 
troponin-I level (≥2.0 ng/mL) or creatine kinase-
myocardial infarction (CK-MB) (19 U/L, exceeding twi-
ce the upper limit of normal), and 3) ischemic changes 
assessed by electrocardiography (ST-segment elevation, 
depression, or T wave inversion of ≥0.2 mV in two 
contiguous leads). Our study included patients in car-
diogenic shock state (Killip class IV). 
We analyzed baseline demographic and clinical cha-
racteristics, relevant laboratory results and pharmacothe-
rapy. Echocardiography was performed in all patients 
before discharge. Major adverse cardiac events (MACE) 
at the 1 month, 6 months, and 1 year clinical follow-up 
were evaluated and were defined as the composite of 1) 
cardiac death, 2) non-cardiac death, 3) non-fatal myocar-
dial infarction (MI), and 4) re-percutaneous coronary 
intervention (PCI) or coronary artery bypass graft (CABG). 
Re-infarction was defined as the recurrence of symptoms 
or electrocardiographic changes in association with a rise 
in cardiac enzymes above the upper limit of normal. All 
data were recorded on a standardized, electronic, web-
based registry at http://www.kamir.or.kr. 
 
Statistical analysis 
We compared the in-hospital mortality, the duration 
of admission to the coronary care unit, and the inciden-
ce of MACE during 1 month, 6 months, and 1 year of 
clinical follow-up between the 2 groups. The predictive 
factors for MACE at the 1 year clinical follow-up were 
calculated by multiple logistic regression analysis. 
The Statistical Package for Social Sciences (SPSS) for 
Windows, version 15.0 (SPSS, Inc., Chicago, IL, USA) 
was used for all analysis. Continuous variables with normal 
distributions were expressed as the mean±standard de-
viation (SD) and they were compared with the use of an 
unpaired Student’s t-test. Categorical variables were com-
pared with the use of the chi-square test, where appro-
priate. A p<0.05 was deemed to be statistically signi-
ficant. 
 
Results 
 
Baseline clinical characteristics of the study 
population 
Among the 2,233 hypertensive patients with AMI who 
were followed-up for 1 year, there were 892 diabetic pa-
tients and 1,342 non-diabetic patients. The baseline cli-
nical characteristics and laboratory findings of the study 
population are described in Table 1 and 2. Hypertensive 
patients with DM were older (p<0.001) and more likely 
to be women (p<0.001). Also, patients with DM had a 
higher proportion of smokers (p<0.001) and hyperlipi-
demia (p=0.007). The diabetic group had lower blood 
pressure (p<0.001), a lower left ventricular ejection frac- 
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tion (p<0.001), more severe heart failure (p<0.001), and 
a higher proportion of ST segment elevation myocardial 
infarction (STEMI; p=0.005). N-terminal pro-brain na-
triuretic peptide level (p<0.001) was higher and creatinine 
clearance (p<0.001) was lower in the diabetic group than 
the non-diabetic group. 
 
Coronary angiographic findings 
In the diabetic hypertension group, coronary angio-
graphy was performed in 92.9% of the patients during 
hospitalization, compared with 95.4% of the patients in 
the non-diabetic hypertension group. Also, PCI was done 
in 89.5% of patients in the diabetic group relative to 
94.4% in the non-diabetic group, but the success rate of 
PCI showed no significant difference between the 2 gro-
ups. The baseline coronary angiographic characteristics 
are shown in Table 3. The most common infarct-related 
artery was the left anterior descending artery in both gro-
ups. The types of lesions according to the American Col-
lege of Cardiology/American Heart Association (ACC/ 
AHA) classification and the Thrombolysis In Myocardial 
Infarction (TIMI) flow grade before and after PCI showed 
no significant differences between the two groups. Left 
main stem and multivessel involvement were more pre 
Table 1. Baseline characteristics according to the presence of diabetes
  Group I (n=892)  Group II (n=1,342)  p 
Mean age (years)  66.2±10.9 63.9±12.8  <0.001 
Male (%)  544 (61.0)  938 (70.0)  <0.001 
Obesity (%)  522 (58.5)  733 (54.7)  <0.068 
Past history (%)       
Smoking  427 (47.9)  775 (57.8)  <0.001 
Hyperlipidemia  341 (38.2)  487 (36.2)  <0.007 
Familial history of coronary artery disesse  68 (7.6)  103 (7.7)  <0.669 
Prior angina  87 (9.8)  88 (6.6)  <0.847 
Prior myocardial infarction  45 (5.1)  50 (3.7)  <0.522 
Prior percutaneous coronary intervention  64 (7.2)  57 (4.3)  <0.486 
Prior coronary artery bypass graft  10 (1.1)  09 (0.7)  <0.829 
Symptoms and hemodynamics on admission       
Chest pain (%)  707 (79.3)  1,115 (83.1)  <0.001 
Dyspnea (%)  259 (29.1)  312 (23.3)  <0.001 
Systolic blood pressure (mmHg)  134.6±31.9 139.7±27.6  <0.001 
Heart rate (beats/min)  81.5±21.2 76.2±17.8  <0.001 
Killip class (%)      <0.001 
I  587 (65.8)  1,050 (78.2)   
II  130 (14.6)  171 (12.7)   
III  106 (11.9)  64 (4.8)   
IV  56 (6.3)  37 (2.8)   
ST-segment elevation myocardial infarction  464 (67.1)  775 (57.8)  <0.005 
Echocardiogram findings       
Left ventricular ejection fraction (%)  49.9±13.2 53.5±12.1  <0.001 
Total wall motion score  17.8±11.0 17.6±10.1  <0.722 
   
Table 2. Laboratory findings according to the presence of diabetes
  Group I (n=892)  Group II (n=1,342)  p 
Creatinine clearance (mL/min)  62.4±29.9 73.0±40.8  <0.001 
CK-MB (U/L)  118.5±169.8 144.7±216.6  <0.001 
Troponin-I (ng/mL)  46.4±76.0 50.2±92.9  <0.368 
Total cholesterol (mg/dL)  188.3±44.6 181.3±47.5  <0.001 
Triglyceride (mg/dL)  139.1±116.6 128.5±85.3  <0.020 
Low density lipoprotein-cholesterol (mg/dL)  116.5±45.2 121.2±42.3  <0.017 
High density lipoprotein-cholesterol (mg/dL)  43.9±13.9 46.3±16.5  <0.001 
High sensitivity C-reactive protein (mg/dL)  30.3±130.7 25.6±119.2  <0.423 
N-terminal pro-brain natriuretic peptide (pg/mL)  4602.5±8710.6 2320.8±5837.9  <0.001 
CK-MB: creatine kinase-myocardial band isoenzyme 
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Table 3. Coronary angiographic findings according to the presence of diabetes
  Group I (n=892)  Group II (n=1,342)  p 
Coronary angiogram, n (%)  829 (92.9)  1,280 (95.4)  <0.009 
Infarct-related artery, n (%)       
Left main stem  25 (3.0)  14 (1.1)  <0.002 
Left anterior descending artery  389 (47.0)  648 (50.6)  <0.113 
Left circumflex artery  138 (16.6)  240 (18.8)  <0.229 
Right coronary artery  277 (33.4)  378 (29.5)  <0.070 
ACC/AHA lesion type, n (%)      <0.666 
A  27 (4.5)  65 (5.1)   
B1  144 (17.2)  207 (16.2)   
B2  184 (22.2)  302 (23.6)   
C  364 (43.9)  546 (42.7)   
Diseased vessel number, n (%)      <0.001 
Single vessel  281 (33.9)  562 (43.9)   
Two vessel  273 (32.9)  425 (33.2)   
Three vessel  275 (33.2)  293 (22.9)   
Percutaneous coronary intervention (PCI)  798 (89.5)  1,267 (94.4)  <0.001 
Successful result of PCI  759 (95.1)  1,225 (96.7)  <0.080 
Pre-PCI TIMI flow grade, n (%)      <0.281 
0  303 (36.5)  524 (40.9)   
I  108 (13.0)  132 (10.3)   
II  149 (18.0)  213 (16.6)   
III 269  (32.5)  411  (32.2)   
Post-PCI TIMI flow grade, n (%)      0.090 
0  19 (2.5)  22 (1.9)   
I  11 (1.5)  10 (0.9)   
II  35 (4.7)  44 (3.7)   
III  685 (91.3)  1,091 (93.5)   
ACC/AHA: American College of Cardiology/American Heart Association, TIMI: Thrombolysis In Myocardial Infarction 
 
Table 4. Clinical outcomes and MACE during follow-up and 12 months after discharge
  Group I (n=892)  Group II (n=1,342)  p 
Outcomes in-hospital period       
In-hospital death, n (%)  87 (9.8)  51 (3.8)  <0.001 
Coronary care unit admission duration (days)  4.5±5.7 3.2±3.0  <0.001 
The composite of MACE at 1 month, n (%)  63 (7.1)  48 (3.8)  <0.001 
Cardiac death  24 (2.7)  12 (0.9)  <0.002 
Non-cardiac death  08 (0.9)  04 (0.3)  <0.061 
Myocardial infarction  12 (1.3)  14 (1.0)  <0.514 
Re-percutaneous coronary intervention  14 (1.6)  17 (1.1)  <0.548 
Coronary artery bypass graft  05 (0.6)  01 (0.1)  <0.028 
The composite of MACE at 6 months, n (%)  147 (16.5)  143 (10.7)  <0.001 
Cardiac death  46 (5.2)  28 (2.1)  <0.001 
Non-cardiac death  14 (1.6)  09 (0.7)  <0.052 
Myocardial infarction  19 (2.1)  19 (1.4)  <0.204 
Re-percutaneous coronary intervention  60 (6.7)  80 (6.0)  <0.460 
Coronary artery bypass graft  08 (0.9)  07 (0.5)  <0.292 
The composite of MACE at 12 months, n (%)  172 (19.3)  165 (12.3)  <0.001 
Cardiac death  53 (5.9)  33 (2.5)  <0.001 
Non-cardiac death  18 (2.0)  12 (0.9)  <0.025 
Myocardial infarction  20 (2.2)  23 (1.7)  <0.374 
Re-percutaneous coronary intervention  72 (8.1)  88 (6.6)  <0.173 
Coronary artery bypass graft  09 (1.0)  09 (0.7)  <0.384 
MACE: major adverse cardiac event    
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valent in the diabetic group than the non-diabetic group 
(p=0.002 and p<0.001 respectively). 
 
In-hospital outcomes and major adverse cardiac 
events 
The clinical outcomes during the 1 year follow-up are 
shown in Table 4. The estimated in-hospital mortality 
was 9.8% in the diabetic group and 3.8% in the non-
diabetic group (p<0.001). The duration of admission to 
the coronary care unit was significantly longer in the dia-
betic group (4.5 vs. 3.2 days, p<0.001). The rates of car-
diac death were higher in the diabetic group at the 1 
month, 6 months, and 12 months clinical follow-ups (p= 
0.002, p<0.001, and p<0.001 respectively). The rates of 
CABG at 1 month and non-cardiac death at 12 months 
were higher in the diabetic group (p=0.028 and p=0.025 
respectively). The incidence of composite MACE was 
higher in the diabetic group at the 1 month, 6 months, 
and 12 months clinical follow-ups (p<0.001, p<0.001, and 
p<0.001 respectively). 
 
Survival curve and multivariate analysis of predic-
tors of 1 year major adverse cardiac events 
The Kaplan-Meier survival curve for mortality showed 
a significantly higher mortality in diabetic hypertensive 
patients (Fig. 1). Multivariate analysis was conducted to 
identify the independent predictors of the 1 year MACE 
using the meaningful factors in univariate analysis (Table 
5 and 6). 
The independent predictors for 1 year MACE were 3-
vessel involvement (p=0.001), presence of DM (p=0.017), 
and a lower ejection fraction (p=0.045) (Table 7). 
 
Discussion 
 
The aim of this study was to examine the relationship 
between DM and clinical outcomes in 2,233 hypertensive 
patients with AMIs in the KAMIR during 12 months of 
follow-up. Our results demonstrated that diabetic hy-
pertensive patients with AMIs have a poorer outcome in 
clinical and angiographic features, and a higher risk of 
death on short- and long-term follow-up relative to non-
diabetic hypertensive patients. 
DM is associated with a high risk of CVD and is the 
leading cause of end-stage renal disease, blindness, and 
non-traumatic amputations. Hypertension by itself is a 
powerful risk factor for cardiovascular morbidity and 
mortality. Although the effects of DM and hypertension 
on the cardiovascular system are often distinct, we can 
easily presume that their combined presence in the same 
patient is devastating to the cardiovascular system. Epi-
Table 5. Univariate analysis for the predictors of 1 year major adverse cardiac events 
  Odd ratio  95% confidence interval  p 
Low ejection fraction (≤40%) 1.848  1.382-2.471  <0.001 
Three vessel involvement  1.697  1.282-2.247  <0.001 
Old age (≥65 years)  1.557  1.204-2.014  <0.001 
Diabetes mellitus  1.555  1.213-1.993  <0.001 
High killip class (≥class III)  1.607  1.142-2.261  <0.009 
Percutaneous coronary intervention  0.631  0.439-0.907  <0.016 
Gender 0.784  0.608-1.013  <0.064 
Treatment of HMG Co-A reductase inhibitor  0.779  0.587-1.035  <0.096 
Treatment of angiotensin converting enzyme inhibitor  0.845  0.654-1.179  <0.154 
Treatment of low molecular weighted heparin  0.834  0.657-1.082  <0.184 
Left main stem disease  1.641  0.713-3.777  <0.217 
Hyperlipidemia 1.271  0.840-1.924  <0.258 
Treatment of platelet glycoprotein IIb/IIIa inhibitor  1.259  0.845-1.876  <0.276 
Treatment of beta blocker  1.191  0.887-1.598  <0.276 
Successful result of percutaneous coronary intervention  0.809  0.545-1.202  <0.286 
Smoking 0.877  0.684-1.125  <0.309 
ST segment elevation myocardial infarction  0.909  0.708-1.167  <0.456 
Treatment of angiotensin receptor blocker  0.873  0.628-1.215  <0.463 
HMG Co-A: 3-hydroxy-3-methylglutaryl coenzyme A   
Fig. 1. Kaplan-Meier survival curves for the 2 groups. Survival cur-
ve analysis reveals significantly higher mortality rate in diabetic 
group than non-diabetic group. 
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demiologic studies have provided evidence for the co-
existence of hypertension and DM and possibly point 
toward a common genetic and environmental factor pro-
moting both DM and hypertension. Similarly, clustering 
of hypertension, insulin resistance, frank type 2 DM, hy-
perlipidemia, and central obesity has been documented 
in several populations.
16) Insulin resistance, increased tis-
sue inflammation, and reactive oxygen species produc-
tion, resulting in endothelial dysfunction, increased tissue 
renin-angiotensin-aldosterone activity, and increased sym-
pathetic nervous system activity have all been implicated 
in this complex pathophysiology of DM and hypertension. 
It is estimated that about 25% to 47% of persons with 
hypertension have insulin resistance or impaired glucose 
tolerance.
17) With insulin resistance there is impaired 
biologic and physiologic tissue responses to insulin. The 
relationship between insulin resistance, DM, and hyper-
tension is complex and interrelated. Untreated patients 
with essential hypertension have higher fasting and post-
prandial insulin levels than age- and gender-matched 
normotensive persons, regardless of body mass; a direct 
correlation between plasma insulin levels and blood pres-
sure exists.
5)18) Interestingly, the relationship between 
hyperinsulinemia and hypertension is not observed in 
secondary hypertension.
18) This indicates that insulin 
resistance and hyperinsulinemia are not consequences 
of hypertension, but rather a genetic predisposition that 
exists for both diseases. This notion is supported by the 
observation that there is abnormal glucose metabolism 
in the offspring of hypertensive patients.
19) Thus, there 
is a strong association between hypertension, DM, and 
insulin resistance. 
Both hypertension and DM are well-identified risk 
factors for atherogenesis. Coronary artery disease is much 
more common in patients with both DM and hyperten-
sion than in patients with hypertension alone, and the 
development of atherosclerosis was found to be accele-
rated, with more plaque fissure and a lower coronary 
perfusion reserve index when DM and hypertension co-
exist.
20)21) Our study revealed that diabetic hypertensive 
Table 7. Multivariate analysis for the predictors of one year major adverse cardiac events
  Odd ratio  95% confidence interval  p 
Multivessel involvement      <0.001 
2 vessel  1.929  1.330-2.799  <0.001 
3 vessel  2.462  1.681-3.605  <0.001 
Diabetes mellitus  1.439  1.068-1.938  <0.017 
Ejection fraction (%)      <0.045 
≤29 1.910  1.218-1.986  <0.011 
30-39 1.696  1.034-2.782  <0.036 
40-49 1.225  0.804-1.868  <0.345 
50-59 1.460  0.777-2.741  <0.239 
60-69 1.039  0.532-2.029  <0.912 
Percutaneous coronary intervention  1.432  0.873-2.351  <0.155 
N-terminal pro-brain natriuretic peptide (pg/mL)  1.110  0.874-1.473  <0.222 
Killip class      <0.614 
II 1.117  0.733-1.703  <0.607 
III 1.416  0.815-2.460  <0.217 
IV 1.270  0.591-2.726  <0.540 
Age     <0.668 
40-49 0.734  0.255-2.113  <0.567 
50-59 0.539  0.194-1.492  <0.234 
60-69 0.612  0.225-1.666  <0.336 
70-79 0.639  0.234-1.741  <0.381 
≥80 0.739  0.254-2.152  <0.579 
Creatinine clearance (mL/min)  1.001  0.993-1.009  <0.792 
 
Table 6. Laboratory findings according to the MACE 
  MACE group  No MACE group  p 
N-terminal pro-brain natriuretic peptide (pg/mL)  5480.8±9034.9 2902.3±6848.1  <0.001 
Creatinine clearance (mL/min)  61.7±29.8 69.1±28.8  <0.001 
CK-MB (U/L)  124.2±187.0 135.3±201.2  <0.354 
MACE: major adverse cardiac event, CK-MB: creatine kindase-myocardial band isoenzyme 
  
 
Min Goo Lee, et al.·249 
patients have a higher prevalence of multivessel involve-
ment than the non-diabetic population following an 
AMI and multivessel disease is related to worse long-
term clinical outcome. Patients with combined DM and 
hypertension also tend to have impaired systolic and dia-
stolic ventricular function with more severe left ventri-
cular hypertrophy and congestive heart failure than coun-
terparts with hypertension alone.
20)22) The extensive 
degenerative changes in the diabetic hypertensive heart 
may be related to abnormalities in the microcirculation. 
The most striking microscopic findings of the hyperten-
sive diabetic heart seem to be the distribution of dense 
interstitial connective tissue throughout the myocardium. 
As expected, we found that in diabetic hypertensive pa-
tients left ventricular ejection fraction was significantly 
lower. In our analysis of patients, the combination of 
DM and hypertension was more common in females, 
but after univariate analysis, the risk of death was not 
significantly different among male and female patients 
as in a previous study.
23) 
The most important result of this study was that DM 
is a strong risk factor for cardiovascular events; hyperten-
sive patients with DM were more likely to have a cardio-
vascular event than non-diabetic hypertensive patients. 
Our study showed that the in-hospital mortality rate for 
diabetic hypertensive patients with an AMI was higher 
than for non-diabetic hypertensive patients. In many pre-
vious studies, hospital case-fatality rates for diabetic pa-
tients with acute coronary syndrome were almost twice 
as high as those for non-diabetic patients.
24-27) Also, these 
results agree with a previous study which reported DM 
to be one of the most important risk factors for new 
cardiovascular events following an AMI.
28) Factors, such 
as diabetic cardiomyopathy, small vessel disease, increased 
platelet activity, decreased fibrinolysis, and autonomic 
neuropathy leading to ventricular arrhythmia may acco-
unt for the poor prognostic outlook of diabetic hyper-
tensive patients.
29)30) In our analysis, long-term clinical 
outcomes of diabetic hypertensive patients following an 
AMI showed worse progression relative to the non-dia-
betic hypertensive population. 
This study had several limitations. First, our study was 
a multi-center prospective registry, and it was not a ran-
domized, controlled study. Thus, there was probably a 
selection bias when enrolling patients into both study 
groups. 
The proportion of STEMI patients was higher in the 
group I patients than in the group II patients. Second, 
a value of blood glucose at follow-up was not recorded 
in the registry, therefore the relationship between adequate 
control of blood glucose and the prognosis of the patie-
nts was not estimated exactly. Third, whether long-term 
and more aggressive treatment of high blood glucose in 
patients with AMI can reduce adverse outcomes remains 
unknown. Finally, the period of our study was relatively 
short because our study was a comparison of the MACE 
at the 1 year clinical follow-up. 
In conclusion, in hypertensive Korean patients with 
AMIs, DM was associated with worse clinical and angio-
graphic features, with a higher risk of development of 
severe heart failure and increased risk of MACE on long-
term clinical follow-up. 
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